From the Journals

U.S. autism rates edge up from 2014-2016


 

FROM JAMA

The prevalence of autism spectrum disorder (ASD) in U.S. children and adolescents climbed to 2.41% from 2014 to 2016, Guifeng Xu, MD, and her associates, wrote in a research letter. However, the increased prevalence of ASD over the 3-year period was not statistically significant.

Devonyu/thinkstock
Of the 30,502 children and adolescents aged 3-17 years old on the National Health Institute Survey included in the study, 711 had been diagnosed with ASD, for the 2.41% prevalence rate. In 2014, the prevalence rate was 2.24%, and the rate was 2.41% in 2015, and 2.58% in 2016.

Males were far more likely to be diagnosed with ASD than females, with respective prevalence rates of 3.54% and 1.22%, from 2014 to 2016.

The results from the NHIS are significantly higher than the last time a nationwide estimate of ASD prevalence was made in 2012, using data from the Autism and Developmental Disabilities Monitoring Network. The ADDM reported a rate of 1.46%, compared with the NHIS rate of 2.41%. Differences in study design and participant characteristics are likely the cause of this difference; the ADDM is conducted at specific sites, while the NHIS is considered to be a nationally representative sample.

“Changes in nonetiologic factors (such as diagnostic criteria, public awareness, and referral), as well as in etiologic factors (including genetic and environmental risk factors), have been postulated to account for the previously observed increase in ASD prevalence,” concluded Dr. Xu, of the department of epidemiology at the University of Iowa, Iowa City, and her associates. “Continued monitoring of the prevalence and investigation of changes in risk factors are warranted.”

Find the full research letter in JAMA (2018;319[1]:81-2. doi: 10.1001/jama.2017.17812).

Recommended Reading

FDA approves generic Strattera for pediatric, adult ADHD patients
MDedge Pediatrics
ADHD – not OCD – called the key comorbidity in pediatric hoarding
MDedge Pediatrics
Mydayis approved for teens, adults with ADHD
MDedge Pediatrics
Cotempla XR-ODT approved for children, adolescents with ADHD
MDedge Pediatrics
Alternative therapies
MDedge Pediatrics
Methylphenidate shows enduring sleep benefits in pediatric ADHD
MDedge Pediatrics
Pediatric seclusion and restraint increases with ADHD, decreases with PTSD
MDedge Pediatrics
ADHD and insomnia appear intertwined
MDedge Pediatrics
Intrauterine exposure to methylphenidate tied to increased cardiac risk
MDedge Pediatrics
MRI-guided neurofeedback improves ADHD long term in adolescent boys
MDedge Pediatrics